$5.94
▼ $-0.17
(-2.78%)
Vol 2.4M
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.4B
ROE
-36.9%
Margin
-14.2%
D/E
131.02
Beta
0.51
52W
$3–$7
Wall Street Consensus
18 analysts · Apr 202610
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
94.4%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.01 | $0.00 | $-0.01 |
| Sep 2025 | $-0.06 | $0.00 | +$0.06 |
| Jun 2025 | $-0.14 | $-0.08 | +$0.06 |
| Mar 2025 | $-0.12 | $-0.17 | $-0.05 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $116.1M | $74.1M | $97.7M | $110.3M | $125.2M |
| Net Income | $4.6M | -$41.1M | -$19.1M | -$969K | -$407K |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -36.6% | -36.6% | -36.6% | -36.9% | -36.9% | -36.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -19.5% | -14.6% | -14.6% | -14.2% | -14.2% | -14.2% |
| Gross Margin | 87.3% | 84.8% | 84.8% | 88.2% | 88.2% | 88.2% |
| D/E Ratio | 144.37 | 144.37 | 144.37 | 131.02 | 131.02 | 131.02 |
| Current Ratio | 4.30 | 4.30 | 4.30 | 4.41 | 4.41 | 4.41 |
Key Ratios
ROA (TTM)
-12.6%
P/S (TTM)
3.56
P/B
6.9
EPS (TTM)
$-0.24
CF/Share
$0.01
Rev Growth 3Y
+220.9%
52W High
$6.78
52W Low
$3.21
$3.21
52-Week Range
$6.78
Financial Health
Free Cash Flow
$20.6M
Net Debt
$140.0M
Cash
$68.0M
Total Debt
$208.0M
As of Dec 31, 2025
How does ARDX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ARDX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
3.6
▼
72%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
6.9
▲
182%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ARDX profitability vs Biotechnology peers
ROE
-36.9%
▲
45%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-14.2%
▲
95%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
88.2%
▲
12%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-12.6%
▲
73%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
ARDX financial health vs Biotechnology peers
D/E ratio
131.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
4.4
▼
1%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
0.5
▼
48%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ARDX fundamentals radar
ARDX
Peer median
Industry
ARDX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ARDX vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
RAAB MICHAEL G
Chief Executive Officer · Mar 16
20833 shs
RAAB MICHAEL G
Chief Executive Officer · Mar 16
41666 shs
RAAB MICHAEL G
Chief Executive Officer · Feb 24
20833 shs
RAAB MICHAEL G
Chief Executive Officer · Feb 24
41666 shs
MOTT DAVID M
Director · Feb 20
333333 shs
RAAB MICHAEL G
Chief Executive Officer · Feb 20
45982 shs
WILLIAMS LAURA A
Officer · Feb 20
8176 shs
KELLIHER MICHAEL
Officer · Feb 20
9595 shs
FOSTER ERIC DUANE
Officer · Feb 20
10439 shs
BRADY JAMES PARKER
Officer · Feb 20
2543 shs
Last 90 days
Top Holders
Top 5: 32.0%Blackrock Inc.
8.62%
$115.8M
Vanguard Group Inc
7.74%
$104.0M
Janus Henderson Group PLC
5.92%
$79.5M
State Street Corporation
4.86%
$65.3M
Millennium Management Llc
4.86%
$65.3M
As of Dec 31, 2025